
A Phase I trial of zzso zzso was undertaken to study its toxicity and to gain preliminary knowledge of its zzso The dose was escalated by increments of 10 from 30 to 70 zzso Out of 20 patients, 19 were zzso for toxicity and response to zzso Hematologic toxicity was dose limiting and dose zzso Other adverse effects included zzso and zzso hair loss, and zzso No acute zzso was zzso In 2 patients with zzso breast cancer who had not been zzso with zzso agents, a partial zzso was achieved lasting for 5 zzso In 6 patients, tumor parameters did not change for a median of 3 months, and 11 patients suffered progressive zzso 

